ReviewBiosensors2026
Electrochemical Detection of Cancer Biomarkers: From Molecular Sensing to Clinical Translation.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early cancer detection is crucial for improving survival rates and treatment outcomes. Electrochemical biosensors have emerged as powerful tools for early cancer detection due to their high sensitivity, specificity, and rapid detection capabilities. This review explores recent advancements (2015-2025) in electrochemical biosensors for cancer biomarker detection, their working principles, novel nanomaterial-based enhancements, challenges, and prospects for clinical applications. Specifically, we highlight the electrochemical detection of protein biomarkers (e.g., CEA, PSA, CRP), nucleic acid markers (ctDNA, miRNA, methylation patterns), and metabolic indicators, emphasizing their clinical relevance in early diagnosis and monitoring. Unlike previous reviews which focus on either biomarker classes or sensor platforms, this review uniquely integrates both factors. This review provides a novel perspective on how next-generation electrochemical biosensors can bridge the gap between laboratory development and real-world cancer diagnostics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.